Drugs / XON7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06154291 | Nov 2023 → Dec 2026 expected | metastatic malignant neoplasm | Xenothera SAS | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-06-12 | Xenothera SAS | Results XENOTHERA reports to ASCO on the clinical trial of its first anti-cancer drug, XON7, and announces a financing agreement with BPI France xenothera.com ↗
The data available as of April 30th, 2024, show that XON7 appears to be well tolerated at doses of 1.5 and 3 mg/kg, with no product-related side-effects or LTD (limiting toxicity dose) observed at this stage . |
| 2023-05-30 | Xenothera SAS | Results [Press Release] XENOTHERA publishes its results at the World Cancer Congress in Chicago (ASCO) June 2-6, 2023. xenothera.com ↗
A l’occasion de l’ASCO, XENOTHERA détaille les propriétés de son quatrième GH-pAb, le XON7, actif contre les tumeurs solides et en hématologie, en publiant deux abstracts. |
All press releases naming this drug 3 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XON7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06154291 ↗ |